Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why
Portfolio Pulse from
JPMorgan's latest research highlights Novo Nordisk and AstraZeneca as top pharma picks for 2025, focusing on their strong drug pipeline developments amid easing US drug pricing concerns and upcoming patent expirations.
December 03, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JPMorgan identifies Novo Nordisk as a top pick for 2025 due to its strong drug pipeline and mid-term growth potential, amid easing US drug pricing concerns.
JPMorgan's positive outlook on Novo Nordisk is based on its promising drug pipeline and expected mid-term growth, which are crucial factors for success in the pharma sector by 2025.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80